Clinical Trials Logo

Recurrent Breast Cancer clinical trials

View clinical trials related to Recurrent Breast Cancer.

Filter by:

NCT ID: NCT00159458 Terminated - Clinical trials for Recurrent Breast Cancer

Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

Start date: July 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if the combination of gemcitabine and oxaliplatin chemotherapy will be effective in reducing or eliminating the tumor(s) in patients with recurrent or metastatic breast cancer. Gemcitabine is a chemotherapy drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic and lung cancer; oxaliplatin is a chemotherapy drug that is approved by the FDA for the treatment of colon cancer. Neither gemcitabine nor oxaliplatin are approved for the treatment of breast cancer. However, both drugs have been shown to decrease the size of breast cancer tumors.

NCT ID: NCT00132002 Terminated - Clinical trials for Stage IV Breast Cancer

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00095888 Terminated - Clinical trials for Stage IV Breast Cancer

3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining 3-AP with gemcitabine in treating patients who have refractory metastatic breast cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining 3-AP with gemcitabine may kill more tumor cells

NCT ID: NCT00079326 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving trastuzumab together with ixabepilone works in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with ixabepilone may kill more tumor cells.

NCT ID: NCT00071942 Terminated - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Start date: October 2003
Phase: Phase 1
Study type: Interventional

Vaccines may make the body build an immune response to kill tumor cells. This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with metastatic breast cancer.

NCT ID: NCT00039455 Terminated - Clinical trials for HER2-positive Breast Cancer

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with flavopiridol may kill more tumor cells. Phase I trial to study the effectiveness of combining trastuzumab with flavopiridol in treating patients who have metastatic breast cancer